Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 33 Researches
7.4
USERS' SCORE
Good
Based on 9 Reviews
8.2
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%**
Saturated Fat
< 0.5 g
2%**
Polyunsaturated Fat
0.5 g
†
Fish Oil Concentrate
1 g (1,000 mg)
†
Omega-3 Fatty Acids:
Eicosapentaenoic Acid (EPA)
180 mg
†
Docosahexaenoic Acid (DHA)
120 mg
†
Top Medical Research Studies
9
We investigated the link between plasma omega-3 levels and the risk of heart failure (HF) in a large UK cohort study. Our analysis revealed that higher omega-3 levels were associated with a 21% lower chance of developing HF over nearly 14 years.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
Read More
9
Omega-3 reduces cardiovascular risk
We observed the effects of icosapent ethyl on heart health in a significant clinical trial involving statin-treated patients at high risk for cardiovascular events. This post hoc analysis revealed that icosapent ethyl reduced major cardiovascular issues, regardless of whether patients had low-density lipoprotein cholesterol (LDL-C) levels below or above 55 mg/dL.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Read More
8
We explored the impact of eicosapentaenoic acid (EPA) on heart health by studying mice on a high-fat diet. Those supplemented with EPA showed a significant reduction in atrial fibrillation compared to those without. While 100% of the high-fat diet mice developed atrial fibrillation, only 50% of those receiving EPA did, and their episodes were shorter.
Our findings suggest that including EPA in the diet can help improve heart function and reduce irregular heart rhythms linked to high-fat diets.
Our findings suggest that including EPA in the diet can help improve heart function and reduce irregular heart rhythms linked to high-fat diets.
Read More
Most Useful Reviews
9
Joint health
NOW Foods Omega-3 Fish Oil provides a strong 1000 mg dose with 180 mg EPA and 120 mg DHA, which reduces fishy aftertaste. The easy-to-swallow capsules offer noticeable benefits for joint health and cardiovascular disease support.
Read More
9
Inflammation reduction
Each softgel provides 1000 mg of fish oil concentrate, delivering 180 mg of EPA and 120 mg of DHA, which are essential for cardiovascular disease, brain function, and reducing inflammation.
Read More
7.5
Mental balance support
1 people found this helpful
Affordable and the best Omega-3 brand I have tried. I take these for myself and add a bit to the food for the feral cats, helping their fur improve. It benefits mental balance and cardiovascular disease.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 33 Researches
7.4
- All Researches
9
Omega-3 reduces cardiovascular risk
We observed the effects of icosapent ethyl on heart health in a significant clinical trial involving statin-treated patients at high risk for cardiovascular events. This post hoc analysis revealed that icosapent ethyl reduced major cardiovascular issues, regardless of whether patients had low-density lipoprotein cholesterol (LDL-C) levels below or above 55 mg/dL.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Notably, those with optimal LDL-C control still benefited from the treatment, showing that this fish oil derivative can be effective in managing heart risks for many patients.
Read More
9
We assessed how omega-3 fatty acids (PUFAs) can support heart failure management through a thorough network meta-analysis of 14 studies with nearly 9,100 participants.
Our findings revealed that high doses (2,000-4,000 mg/day) taken for at least one year significantly improved heart function, particularly the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter durations were not effective, and we found no major differences in safety measures like dropout rates or overall mortality between those taking omega-3 and those who were not.
Our findings revealed that high doses (2,000-4,000 mg/day) taken for at least one year significantly improved heart function, particularly the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter durations were not effective, and we found no major differences in safety measures like dropout rates or overall mortality between those taking omega-3 and those who were not.
Read More
9
We investigated the link between plasma omega-3 levels and the risk of heart failure (HF) in a large UK cohort study. Our analysis revealed that higher omega-3 levels were associated with a 21% lower chance of developing HF over nearly 14 years.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
For individuals already diagnosed with HF, elevated omega-3 levels corresponded to about a 50% reduction in the risk of overall and cardiovascular mortality. These results suggest that boosting omega-3 intake through diet or supplements may help prevent HF and increase longevity for those already facing heart challenges.
Read More
9
We delved into how Antarctic krill oil, rich in eicosapentaenoic acid (EPA), can influence cardiovascular health, specifically in the context of obesity. Our focus centered on its effects in mice fed a high-fat diet, which typically leads to increased cholesterol levels and oxidative stress—conditions that can heighten cardiovascular disease risk.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Read More
8
This study examined how different fatty acids affect heart health, particularly focusing on long-chain acylcarnitines. We found that saturated and monounsaturated acylcarnitines, especially one type called trans-elaidoylcarnitine, can significantly harm heart function and cell viability.
On the other hand, omega-3 derived acylcarnitines like eicosapentaenoylcarnitine and docosahexaenoylcarnitine showed minimal negative effects. In fact, they did not impair heart function or cell viability, suggesting that omega-3 fish oil might be a safer option for people with heart issues compared to other fatty acid sources.
On the other hand, omega-3 derived acylcarnitines like eicosapentaenoylcarnitine and docosahexaenoylcarnitine showed minimal negative effects. In fact, they did not impair heart function or cell viability, suggesting that omega-3 fish oil might be a safer option for people with heart issues compared to other fatty acid sources.
Read More
User Reviews
USERS' SCORE
Good
Based on 9 Reviews
8.2
- All Reviews
- Positive Reviews
- Negative Reviews
9
Joint health
NOW Foods Omega-3 Fish Oil provides a strong 1000 mg dose with 180 mg EPA and 120 mg DHA, which reduces fishy aftertaste. The easy-to-swallow capsules offer noticeable benefits for joint health and cardiovascular disease support.
Read More
9
Inflammation reduction
Each softgel provides 1000 mg of fish oil concentrate, delivering 180 mg of EPA and 120 mg of DHA, which are essential for cardiovascular disease, brain function, and reducing inflammation.
Read More
7.5
Mental balance support
1 people found this helpful
Affordable and the best Omega-3 brand I have tried. I take these for myself and add a bit to the food for the feral cats, helping their fur improve. It benefits mental balance and cardiovascular disease.
Read More
7.5
Risk reduction
Consuming omega-3 fatty acids EPA and DHA may reduce the risk of cardiovascular disease.
Read More
7.5
Quality assurance
This fish oil concentrate, manufactured under strict quality control standards, may reduce the risk of cardiovascular disease due to its EPA and DHA content. These enteric-coated softgels are suitable for those who experience reflux from other fish oils.
Read More
Frequently Asked Questions
7.5
Blood pressure control
Omega-3 is great for cardiovascular disease and managing blood pressure issues as I age. It effectively controls blood pressure surges when taken regularly.
7.5
Mental balance support
1 people found this helpful
Affordable and the best Omega-3 brand I have tried. I take these for myself and add a bit to the food for the feral cats, helping their fur improve. It benefits mental balance and cardiovascular disease.
9
Joint health
NOW Foods Omega-3 Fish Oil provides a strong 1000 mg dose with 180 mg EPA and 120 mg DHA, which reduces fishy aftertaste. The easy-to-swallow capsules offer noticeable benefits for joint health and cardiovascular disease support.
7.5
Quality assurance
This fish oil concentrate, manufactured under strict quality control standards, may reduce the risk of cardiovascular disease due to its EPA and DHA content. These enteric-coated softgels are suitable for those who experience reflux from other fish oils.
7.5
Risk reduction
Consuming omega-3 fatty acids EPA and DHA may reduce the risk of cardiovascular disease.
7.5
Cholesterol improvement
The high-quality ingredients in these enteric-coated softgels may reduce the risk of cardiovascular disease. They help in lowering harmful cholesterol, reducing inflammation, and enhancing skin, hair, and nail health.
9
Inflammation reduction
Each softgel provides 1000 mg of fish oil concentrate, delivering 180 mg of EPA and 120 mg of DHA, which are essential for cardiovascular disease, brain function, and reducing inflammation.
9
We assessed how omega-3 fatty acids (PUFAs) can support heart failure management through a thorough network meta-analysis of 14 studies with nearly 9,100 participants.
Our findings revealed that high doses (2,000-4,000 mg/day) taken for at least one year significantly improved heart function, particularly the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter durations were not effective, and we found no major differences in safety measures like dropout rates or overall mortality between those taking omega-3 and those who were not.
Our findings revealed that high doses (2,000-4,000 mg/day) taken for at least one year significantly improved heart function, particularly the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter durations were not effective, and we found no major differences in safety measures like dropout rates or overall mortality between those taking omega-3 and those who were not.
8
We examined how eicosapentaenoic acid (EPA), alongside other omega-3 fatty acids, might influence the risk of sudden cardiac death (SCD) and cardiovascular disease (CVD) mortality. Our analysis included findings from ten prospective cohort studies, involving over 310,000 participants and averaging 8.7 years of follow-up.
We found a promising inverse relationship between EPA levels in the blood and the incidence of SCD. Specifically, higher circulating levels of omega-3s were linked to a reduced risk. Our results indicated that individuals with high levels of combined omega-3 fatty acids (EPA, DHA, and DPA) had about 45% lower risk of SCD and CVD mortality compared to those with lower levels. This suggests that increasing our intake of omega-3s, particularly EPA, may contribute to heart health.
In summary, the evidence points towards a potential benefit of higher EPA levels in protecting against serious heart issues. While the overall understanding continues to evolve, these findings could guide future dietary recommendations and heart health strategies.
We found a promising inverse relationship between EPA levels in the blood and the incidence of SCD. Specifically, higher circulating levels of omega-3s were linked to a reduced risk. Our results indicated that individuals with high levels of combined omega-3 fatty acids (EPA, DHA, and DPA) had about 45% lower risk of SCD and CVD mortality compared to those with lower levels. This suggests that increasing our intake of omega-3s, particularly EPA, may contribute to heart health.
In summary, the evidence points towards a potential benefit of higher EPA levels in protecting against serious heart issues. While the overall understanding continues to evolve, these findings could guide future dietary recommendations and heart health strategies.
4
Genetics influence omega-3 effectiveness
We aimed to evaluate how genetic factors influence the effectiveness of fish oil supplementation on fatty acid profiles in healthy individuals.
In this study, 86 adults participated in a 4-week fish oil program, and their lipid profiles were assessed before and after the supplementation.
We found that genetic variations, specifically in the FADS1 and ELOVL2 genes, might affect how well the body utilizes omega-3 fatty acids.
This highlights the potential for personalized nutrition to enhance cardiovascular health.
In this study, 86 adults participated in a 4-week fish oil program, and their lipid profiles were assessed before and after the supplementation.
We found that genetic variations, specifically in the FADS1 and ELOVL2 genes, might affect how well the body utilizes omega-3 fatty acids.
This highlights the potential for personalized nutrition to enhance cardiovascular health.
8
We explored the impact of eicosapentaenoic acid (EPA) on heart health by studying mice on a high-fat diet. Those supplemented with EPA showed a significant reduction in atrial fibrillation compared to those without. While 100% of the high-fat diet mice developed atrial fibrillation, only 50% of those receiving EPA did, and their episodes were shorter.
Our findings suggest that including EPA in the diet can help improve heart function and reduce irregular heart rhythms linked to high-fat diets.
Our findings suggest that including EPA in the diet can help improve heart function and reduce irregular heart rhythms linked to high-fat diets.
References
- Liepinsh E, Gukalova B, Krims-Davis K, Kuka J, Leduskrasta A, et al. EPA and DHA acylcarnitines are less cardiotoxic than are saturated and monounsaturated long-chain acylcarnitines. Biofactors. 2025;51:e70014. doi:10.1002/biof.70014
- Medoro A, Graziano F, Cardinale G, Voccola S, Zotti T, et al. The influence of FADS1 and ELOVL2 genetic polymorphisms on polyunsaturated fatty acid composition in response to fish oil supplementation. Lipids Health Dis. 2025;24:102. doi:10.1186/s12944-025-02513-w
- Horii K, Ono K, Sumi T, Higashihara M, Zaima N, et al. Eicosapentaenoic acid prevents atrial electrocardiographic impairments and atrial fibrillation in high fat diet mice. J Physiol Sci. 2025;75:100014. doi:10.1016/j.jphyss.2025.100014
- Dawczynski C, Drobner T, Weidauer T, Schlattmann P, Kiehntopf M, et al. Reduction of cardiovascular risk factors by the diet - Evaluation of the MoKaRi concept by a parallel-designed randomized study. Lipids Health Dis. 2025;24:88. doi:10.1186/s12944-025-02500-1
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. doi:10.1161/JAHA.124.038656
- Mao Q, Tian X, Wang X, Xu H, Zhang Y, et al. Global burden of cardiovascular diseases attributable to diet low in seafood omega-3 fatty acids from 1990~2021 and forecasting the future trends: A population-based study. PLoS One. 2025;20:e0316767. doi:10.1371/journal.pone.0316767
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. doi:10.1016/j.advnut.2025.100366
- Hemmati R, Bahrami Zanjanbar D, Shishesaz MI, Soleimani A, Yari T. The impact of Omega-3 supplementation on arrhythmia reduction in acute coronary syndrome patients: a randomized clinical trial. J Complement Integr Med. 2025;22:173. doi:10.1515/jcim-2024-0427
- Wang Y, Wu G, Wang Y, Rehman A, Yu L, et al. Recent developments, challenges, and prospects of dietary omega-3 PUFA-fortified foods: Focusing on their effects on cardiovascular diseases. Food Chem. 2025;470:142498. doi:10.1016/j.foodchem.2024.142498
- Dong S, Wang Y, Bian J, Chen H, Dong J, et al. The effect of omega-3 Polyunsaturated Fatty Acid (PUFA) prescription preparations on the prevention of clinical cardiovascular disease: a meta-analysis of RCTs. Nutr J. 2024;23:157. doi:10.1186/s12937-024-01051-y
- Jawad MA, O'Keefe JH, Tintle N, O'Keefe EL, Franco WG, et al. Association of Plasma Omega-3 Levels With Incident Heart Failure and Related Mortalities. Mayo Clin Proc. 2024;99:1895. doi:10.1016/j.mayocp.2024.08.007
- Brosolo G, Da Porto A, Marcante S, Capilupi F, Bertin N, et al. The role for ω-3 polyunsaturated and short chain fatty acids in hypertension: An updated view on the interaction with gut microbiota. Eur J Pharmacol. 2024;985:177107. doi:10.1016/j.ejphar.2024.177107
- Lee YQ, Tan KH, Chong MF. Biomarkers of PUFA and cardiovascular risk factors and events in healthy Asian populations: a systematic review. Br J Nutr. 2024;132:1474. doi:10.1017/S0007114524002708
- Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. doi:10.1038/s44319-024-00271-x
- Li ZH, Song WQ, Qiu CS, Li HM, Tang XL, et al. Fish oil supplementation, genetic susceptibility and risk of new-onset hypertension. Prev Med. 2024;189:108152. doi:10.1016/j.ypmed.2024.108152
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. doi:10.1016/j.ajcnut.2025.02.028
- Liboriussen C, Nygaard L, Jensen JD, Schmidt EB, Glerup RI, et al. Low Plasma Marine N-3 Polyunsaturated Fatty Acids are Associated with Increased Risk of Cardiovascular Events in Patients Treated with Maintenance Hemodialysis. J Ren Nutr. 2025. doi:10.1053/j.jrn.2025.02.001
- Yunoki K, Matsumi H, Miyoshi T, Kubo M, Hata Y, et al. Clinical Significance of Serum Omega-3 Fatty Acids on Endothelial Function in Patients with Coronary Artery Disease Under Statin Therapy. J Cardiovasc Dev Dis. 2025;12. doi:10.3390/jcdd12020060
- Patil T, Gregory M, Savona N, Jarmukli N, Leonard CE. Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints. Clin Drug Investig. 2025;45:69. doi:10.1007/s40261-024-01417-4
- Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. doi:10.3390/jcm14010026
- Lamon-Fava S. Associations between omega-3 fatty acid-derived lipid mediators and markers of inflammation in older subjects with low-grade chronic inflammation. Prostaglandins Other Lipid Mediat. 2025;176:106948. doi:10.1016/j.prostaglandins.2025.106948
- Fukuda T, Nakajima T, Hasegawa T, Amano H, Arikawa T, et al. Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease. Cureus. 2024;16:e73417. doi:10.7759/cureus.73417
- O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. doi:10.1016/j.pcad.2024.11.003
- Choi JH, Park SE, Kim S. Antarctic Krill Oil Supplementation Attenuates Hypercholesterolemia, Fatty Liver, and Oxidative Stress in Diet-Induced Obese Mice. Nutrients. 2024;16. doi:10.3390/nu16213614
- So J, Yao JH, Magadmi R, Matthan NR, Lamon-Fava S. Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2024;203:102655. doi:10.1016/j.plefa.2024.102655
- Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. doi:10.3389/fnut.2024.1423228
- Follonier C, Rabassa G, Branca M, Carballo D, Koskinas K, et al. Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes. Atheroscler Plus. 2024;58:1. doi:10.1016/j.athplu.2024.09.002
- Koutsaliaris IK, Pantazi D, Tsouka AN, Argyropoulou O, Tellis CC, et al. Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. Int J Mol Sci. 2024;25. doi:10.3390/ijms251810136
- Ren Y, Chen B, Zhang H, Xu S. A cohort study reveals shared and distinct serum metabolic biomarkers for major adverse cardiovascular events in middle-aged and older adults. Geroscience. 2025. doi:10.1007/s11357-025-01544-6
- Arghavani H, Bilodeau JF, Rudkowska I. Association Between Circulating Fatty Acids and Blood Pressure: A Review. Curr Nutr Rep. 2025;14:15. doi:10.1007/s13668-024-00602-3
- Li J, Guo J, Yuen M, Yuen H, Peng Q. The comparative effects of ω-7 fatty acid-rich sea buckthorn oil and ω-3 fatty acid-rich DHA algal oil on improving high-fat diet-induced hyperlipidemia. Food Funct. 2025;16:1241. doi:10.1039/d4fo04961f
- Berkowitz L, Echeverría G, Salazar C, Faúndez C, Coe CL, et al. Lipidomic Signature of Healthy Diet Adherence and Its Association with Cardiometabolic Risk in American Adults. Nutrients. 2024;16. doi:10.3390/nu16233995
- Shi F, Chowdhury R, Sofianopoulou E, Koulman A, Sun L, et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. Eur J Prev Cardiol. 2025;32:233. doi:10.1093/eurjpc/zwae315
